| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
VP, Research
1 company
Jeff Fairman last filed a Form 4 in December 2022, as VP, Research at PCVX. Jeff Fairman's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Jeff Fairman a below-average insider score of 44/100, based on 19 past trades. Over a 12-month horizon, 15.8% of those trades were profitable, with an average 12-month return of -54.6%.
At the last filing, the largest reported position was 286,227 shares of PCVX. The PCVX filings lean toward selling, a net 112,000 shares.
Jeff Fairman has 26 Form 4 filings on record from December 2020 to December 2022, all as VP, Research at Vaxcyte (PCVX), 2020–2022.
The 51 reported transactions were 30 open-market sales, 16 option exercises, 3 option or other derivative awards and 1 tax withholding, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 20 sales worth about $2.9M.
The largest open-market sale was 10,000 shares of PCVX at an average $40.00 on October 26, 2022, about $400K. Twelve months later PCVX was up 18%.
Shares as reported in the last Form 4 for each company; the most recent is from December 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 26, 2022 | PCVX Vaxcyte, Inc. | VP, Research | Sell | 10,000 | $40.00 | $400,000.00 | -3.4% | +10.6% | +18.3% | |
| Oct 11, 2022 | PCVX Vaxcyte, Inc. | VP, Research | Sell | 5,000 | $25.50 | $127,500.00 | -1.7% | +84.3% | +93.0% | |
| Sep 6, 2022 | PCVX Vaxcyte, Inc. | VP, Research | Sell | 5,000 | $26.58 | $132,892.13 | -1.6% | +71.4% | +96.4% | |
| Aug 5, 2022 | PCVX Vaxcyte, Inc. | VP, Research | Sell | 15,000 | $25.57 | $383,507.50 | -4.7% | +72.8% | +91.5% | |
| May 20, 2022 | PCVX Vaxcyte, Inc. | VP, Research | Sell | 4,112 | $25.50 | $104,856.00 | -1.3% | -0.2% | +83.9% | |
| May 5, 2022 | PCVX Vaxcyte, Inc. | VP, Research | Sell | 888 | $25.80 | $22,914.40 | -0.3% | -0.3% | +109.3% | |
| Apr 5, 2022 | PCVX Vaxcyte, Inc. | VP, Research | Sell | 5,000 | $25.59 | $127,950.00 | -1.5% | -9.2% | +46.5% | |
| Mar 11, 2022 | PCVX Vaxcyte, Inc. | VP, Research | Sell | 10,000 | $25.50 | $255,000.00 | -2.9% | -21.7% | +55.7% | |
| Dec 27, 2021 | PCVX Vaxcyte, Inc. | VP, Research | Sale+OE | 4,750 | $23.60 | $112,092.50 | -43.5% | +2.0% | +96.7% | |
| Dec 16, 2021 | PCVX Vaxcyte, Inc. | VP, Research | Sale+OE | 4,619 | $22.50 | $103,927.50 | -42.9% | +23.8% | +115.8% |